

Review

Intracoronary Diagnostics in Patients with Acute Coronary SyndromeQianhui Sun^{1,2}, Minghao Liu^{1,2}, Ming Zeng^{1,2}, Haibo Jia^{1,2,*}¹Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, 150086 Harbin, Heilongjiang, China²Key Laboratory of Myocardial Ischemia, Harbin Medical University, 150086 Harbin, Heilongjiang, China*Correspondence: jhb101180@163.com (Haibo Jia)

Academic Editors: Carlo Briguori and Salvatore De Rosa

Submitted: 12 October 2022 Revised: 3 December 2022 Accepted: 12 December 2022 Published: 6 February 2023

Abstract

Despite the increasing number of coronary interventions in China, long-term adverse cardiovascular events remain high, especially in patients with acute coronary syndromes (ACS). The advent of intracoronary imaging and coronary physiological diagnostic techniques, such as optical coherence tomography (OCT), intravascular ultrasound (IVUS), near infrared spectroscopy (NIRS), and flow reserve fraction (FFR), has optimized the diagnosis and risk classification of patients with ACS. Intracoronary diagnostics compensate for the deficiencies of conventional coronary angiography in identifying and incriminating lesions and high-risk lesions. The combination of intracoronary imaging and physiological techniques is expected to achieve a comprehensive evaluation of the structural features and physiology of the coronary arteries, thus further tailoring and improving the prognosis of patients.

Keywords: acute coronary syndrome; intracoronary imaging; coronary physiology**1. Overview of Acute Coronary Syndrome**

Coronary heart disease (CHD) is the most common clinical manifestation of atherosclerosis. Acute coronary syndrome (ACS), considered the most severe type of CHD, poses a serious threat to human life [1]. ACS usually includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris. Among these, myocardial infarction is typically due to myocardial cell necrosis caused by prolonged ischemia [2]. Coronary atherosclerosis is a major cause of ACS. Atherosclerosis is usually considered to be the formation of a thrombus blocking the lumen area due to injured vascular endothelial lesions, which leads to a sharp decrease in coronary blood flow. In recent years, the prognosis of ACS patients has dramatically improved with the development of percutaneous coronary intervention (PCI) and cardiovascular medicine. Coronary angiography used to be the gold standard for diagnosing CHD. Nevertheless, like traditional two-dimensional imaging, it has certain limitations. The inability to accurately evaluate the pathophysiological mechanism, plaque burden (PB), plaque characteristics, and stent lesions, may lead to misjudgment of lesion characteristics and suboptimal treatment.

The 2018 ESC/EACTS guidelines emphasize the importance of using intracoronary imaging techniques to aid in the precise diagnosis of patients with myocardial infarction [3]. For culprit lesions, the current guidelines point out that treatment decisions should be made based on lesion types and characteristics, such as considering conservative treatment for plaque erosion and rotational atherectomy for large calcified nodules. Such treatments may reduce the number

of stents implantation and the incidence of related complications without affecting long-term outcomes [3,4].

In addition to treating culprit lesions, the treatment of non-culprit lesions is also an essential step in improving the prognosis of patients. Several clinical trials have shown that over half of ACS patients have non-culprit lesions [5–7] that may develop later and lead to new adverse events. Accordingly, we must also pay attention to these non-culprit lesions and further explore suitable treatment strategies. Intracoronary imaging modalities enable the operator to have a deeper understanding of the internal structure and lesion characteristics of coronary arteries in ACS patients and to optimize the selection of diagnosis and treatment schemes [8,9]. For ACS patients, intracoronary imaging and physiological technology have become increasingly important in optimizing the comprehensive treatment of culprit and non-culprit lesions.

2. Optimization of Diagnosis and Treatment of Patients with Coronary Heart Disease by Intracoronary Examination

At present, there are two main types of intracoronary examination methods. The first involves intracoronary imaging technology, including optical coherence tomography (OCT), coronary intravascular ultrasound (IVUS), and near-infrared spectroscopy (NIRS). The second entails coronary physiological evaluation, such as fractional flow reserve (FFR). Compared to angiography, intracoronary imaging techniques can provide more information on the structural characteristics of plaques with higher resolution and tissue differentiation. Currently, they are the best means for assessing plaque morphological characteristics.



OCT is based on depth-resolved infrared reflection, with an axial resolution of about 10–15 μm and penetration depth of 0.1–2.0 mm. OCT can clearly distinguish plaque composition and structure [10]. However, OCT requires complete blood clearance from the lumen for high-quality imaging since red blood cells cause scattering of the light. IVUS is another common intracoronary imaging technology used to observe coronary plaque. Introduced by Yock *et al.* [11] in the 1980s, IVUS is the first real-time and high-resolution intracoronary imaging device. Its imaging is primarily carried out by collecting and processing acoustic signals. Although the axial resolution of IVUS is about 150 μm , which is less than that of OCT, its penetration depth can reach 8.0–10.0 mm. IVUS thus allows real-time tomographic assessment of the deep contents of plaque and the full-thickness structure of the blood vessel wall, such as media and adventitia; it also permits evaluation of the vascular remodeling. These features play a more significant role in guiding the treatment of coronary diseases in large lumens, such as the left main blood vessel [12,13]. NIRS is a spectrum-based analysis that has high accuracy in identifying lipid and plaque components by using different optical reflections on tissues. In human experiments, the accuracy and specificity of NIRS in identifying lipid components are over 90% [14].

2.1 Accurate Identification of Culprit Plaque by Intracoronary Imaging Tools

For patients with typical acute chest pain or accompanying ST-segment elevation of electrocardiogram, intracoronary imaging can accurately delineate the continuity of vascular lumen, plaque disruption, and associated thrombus to determine the culprit lesion [15]. The most common cause of ACS events is coronary atherosclerosis, whereby the normal triple-layered structure of the vessel wall is absent on the intracoronary image picture. OCT, with its superior resolution, permits clearer visualization of plaque-specific features. Its accuracy has been well demonstrated in correlation with histology [16]. In OCT images, the fibrous component usually appears as a highly expressed region of uniform signal. The lipid component in OCT usually appears as a low-signal region with diffuse boundaries [17,18]. However, due to the strong attenuation of the lipid component to the light signal, it is generally difficult to observe the posterior border of the lipid and the deep tissue components.

Plaque rupture is the most frequently observed substrate for ACS, accounting for approximately 60%–80% of cases. Defined as the discontinuity of the fibrous cap, it leads the underlying necrotic core components, such as lipids, to communicate with the lumen. Typically, a signal-free cavity inside the plaque can be seen by OCT or IVUS at the fibrous cap rupture, where the necrotic core is washed away by blood flow or optical contrast media. These components promote the formation of (generally red) throm-

bus, which is rich in red blood cells and leads to a sharp decrease in the lumen area [19]. In this context, thrombosis and vasoconstriction may lead to acute cessation of the coronary blood flow and subsequent myocardial ischemia [20]. Nowadays, clinical treatment tends to recommend stent treatment for most ruptured plaques. Compared with the other type of plaque, plaque rupture has more lipid components and poorer prognosis [21].

The second most common lesion type is plaque erosion, accounting for about 30% of cases. Characterized by an intact fibrous cap, it is typically accompanied by the formation of local platelet-rich white thrombus, blocking blood vessels and is usually attributed to the attenuation of vascular endothelial cells [22,23]. However, although the endothelial cells are undetectable by current imaging modalities, OCT is the only tool that may identify plaque erosion with its high resolution in clinical settings. Jia *et al.* [24] preliminarily determined the diagnostic criteria of plaque erosion by detection of 126 ACS patients on OCT: A “definite” plaque erosion is described as the absence of fibrous cap disruption, in a lesion frequently composed of fibrous tissue with overlying luminal white thrombus. A “possible” OCT-plaque erosion is defined as an irregular luminal surface without evident thrombus or an overlying thrombus with attenuation of the underlying plaque, without evidence of superficial lipid or calcification in the vessel upstream or downstream of the thrombus site [24].

Several studies of plaque erosion by OCT have demonstrated that the clinical characteristics of plaque erosion patients usually present with the characteristics of young age (<55 years old), smoking, female, and often present in the form of NSTEMI [24]. Erosion plaque is usually characterized by less stenosis, a thicker fibrous cap, and shorter plaque length [24]. Some specialist suggests that such patients may achieve a better prognosis with less severe vessels compared to those with ruptured plaques [25]. In addition, by observing the pathophysiological mechanism of plaque erosion, some studies suggest that a conservative non-stenting strategy may achieve a better prognosis than traditional stents for some plaque erosion with large lumen area and residual diameter stenosis less than 70% [15,26–28]. According to the latest EROSION III study comparing angiography and OCT-guided PCI treatment, the number of stents implanted was reduced in the OCT group compared to angiography (15%), while similar prognosis was shown in both groups [4]. This trial again demonstrated the safety of non-stenting strategy and the importance of OCT for optimizing PCI strategies.

The calcified nodule is usually associated with a calcified plate with fibrous cap disruption, overlaid by a thrombus. When the calcification is thin enough for light to penetrate, OCT can accurately identify the boundary and angle of calcification with sharp borders presenting with signal-poor regions. Calcification can be divided into three types under OCT: eruptive calcified nodules, superficial calcific

sheet, and calcified protrusion. Superficial calcification, the most frequent type, often occurs in the left anterior descending coronary arteries, and is likely associated with the most significant post-intervention myocardial damage [29]. Although calcified nodules are relatively rare compared with the other two types, it can pose significant challenges for selecting stent sites and proper stent implantation, like heavy local calcification may lead to poor stent expansion. The factors affecting the adverse effects of stent expansion include lesions with calcium deposit with maximum angle $>180^\circ$, maximum thickness >0.5 mm, and length >5 mm [30], suggesting that adequate pre-treatment should be given due attention. Previous IVUS studies have also pointed out that superficial calcium angle $>270^\circ$, longer than 5 mm, 360° of superficial calcium, calcified nodule, and vessel diameter <3.5 mm are all independently related to poor stent expansion rate [31]. Accurate identification of calcification types is beneficial to individualized guidance of stent placement and improvement of the prognosis [32].

Non-obstructive myocardial infarction (MINOCA) is also one of the causes of ACS, typically presenting with less than 50% coronary stenosis. Previous studies have pointed out that MINOCA patients' 12-month mortality rate can reach 4.7%, much higher than that of the non-ACS population [33]. Another study also noted greater mortality from non-cardiac causes during one-year follow-up in the MINOCA population compared to the NSTEMI population [34]. Common causes of MINOCA include plaque rupture, plaque erosion, coronary artery spasm (CAS), coronary microvascular spasm, and spontaneous artery coronary dissection [2]. CAS is an important etiology of MINOCA, as spasm causes vasoconstriction and subsequent epicardial or transmural myocardial ischemia with transient ST-segment changes. Usually, CAS can be confirmed by provocation test. However, some researchers have disputed the prognostic significance of provocation test in ACS [35], suggesting that it may risk potential arrhythmias or other adverse event in acute stage. Therefore, provocation test is not currently recommended for clinical use. However, a trial exploring patients with AMI by using this test obtained the opposite result [36]. The results of an intraoperative acetylcholine and ergometrine provocation test combining OCT suggest that patients with positive result had a poorer prognosis and were mainly characterized by major adverse cardiovascular events (MACE), especially death, ACS or revascularization [36]. This trial confirms the safety and efficacy of OCT combined with acetylcholine and ergometrine provocation test for intracoronary diagnosis of CAS and identification of MINOCA etiology. Notably, although nonspecific vasodilators are the current standard of care for CAS, the clinical prognosis of the patients in this trial was still suboptimal, possibly owing to the limited current pharmacological treatment options and the fact that most of the patients had drug-refractory angina [37,38].

In addition, it has been suggested that abnormal microcirculatory function may be a possible important cause of MINOCA [39,40]. Microvascular overreaction to vasoconstrictors can also lead to myocardial ischemia. The common invasive procedures used to assess microvascular function include (1) impaired endothelial non-dependent function, as measured by coronary flow reserve (CFR) and index microvascular resistance (IMR), and (2) endothelium-dependent function, which need the use of pharmacological stimuli to induce [41]. Among these, CFR refers to the maximum increase in coronary blood flow above resting values after coronary vasodilation, reflecting the combined vasodilatory capacity of epicardial and microvascular coronary arteries. CFR should be assessed together with FFR (response to the degree of epicardial stenosis) when used alone to assess microvessels. Two randomized clinical trials are currently investigating whether customized drug therapy for MINOCA based on the results of adjuvant invasive testing can improve prognosis (NCT05198791 and NCT05122780).

Intracoronary imaging tools, especially OCT, helps to observe thrombosis without prominent atherosclerotic plaque or to find possible thromboembolism or vasospasm and other non-atherosclerotic lesions. Therefore, for patients with atypical ACS, intracoronary imaging is helpful for accurate diagnosis of ACS [42], as it can identify culprit and non-culprit lesions and avoid unnecessary exposure of antiplatelet drugs and anticoagulants.

2.2 Accurate Identification of Vulnerable Non-Culprit Lesions by Intracoronary Imaging Tools

As mentioned, the intracoronary imaging tool can delineate the surface structure characteristics of plaque, microchannels, cholesterol crystals, and other important related data [43]. It can divide plaque into vulnerable and non-vulnerable portions by identifying the attributes of non-culprit lesions. It is generally believed that the recurrent adverse events in some patients with ACS after an operation are secondary to vulnerable plaques. In other words, plaques with a large lipid core, thin fibrous cap, and rich macrophages are prone to progress rapidly in a short time or even lead to events, including cardiac death during short-term and long-term follow-up. Moreover, vulnerable plaques in ACS patients usually reside in segments with tight stenosis in the epicardial coronary arteries [44]. In addition, an experiment using OCT specifically to explore ACS patients obtained similar conclusions: Plaques equipped with lipid plaque (maximum lipid angle $>180^\circ$) and thin fibrous cap plaque (thinnest fibrous cap thickness <65 μm) have a higher risk [45]. It has been demonstrated that in patients with STEMI, those containing non-culprit lesions characterized by thin fibrous cap thickness (TCFA) (lipid angle $>90^\circ$, mean fibrous cap thickness <65 μm) have more severe lesions [46].

Table 1. The summary of studies illustrating vulnerable plaques identified by intracoronary imaging in ACS patients.

Study	Technology	Vulnerable characteristic	Reference
ATHEROREMO-IVUS	IVUS-NIRS	IVUS virtual histology-derived TCFA; PB $\geq 70\%$	[51,52]
PROSPECT2	IVUS-NIRS	Max LCBI4mm ≥ 324.7 ; PB $\geq 70\%$	[53]
Wenbin Zhang <i>et al.</i>	IVUS-OCT	ACS presentation was related to plaque vulnerability (more TCFA, more lipid and macrophages, larger PB and positive remodeling)	[54]
Francesco Prati <i>et al.</i>	IVUS-OCT	MLA $< 4 \text{ mm}^2$, FCT $< 75 \mu\text{m}$ predicts acute events	[55]

PB, Plaque Burden.

Moreover, IVUS has been also used to study vulnerable plaques *in vivo* for the last ten years. The PROSPECT study, including 697 ACS patients, is a large-scale prospective multicenter trial. After a median follow-up of 3.4 years, it confirmed that the thin fibrous cap plaque, PB $\geq 70\%$, and minimum lumen area (MLA) $\leq 4.0 \text{ mm}^2$ observed by virtual histology-intravascular ultrasound (VH-IVUS) are closely related to the poor prognosis of patients [7]. This result showed that about one-fifth of non-culprit lesions are closely related to recurrent events, emphasizing the importance of early identification of high-risk lesions. Although the lateral resolution of IVUS is far inferior to that of OCT, the recently developed 60-MHz high-resolution intravascular ultrasound (HR-IVUS), as a new generation of IVUS, has dramatically improved its sensitivity in plaque recognition [47].

The lipid core burden index (LCBI) was the main index for evaluating vulnerable plaques by NIRS. Max LCBI4mm was more commonly used [48,49]. Schuurman *et al.* [50] use NIRS and IVUS to predict high-risk plaque progressing to recurrent events which includes 117 ACS patients. The results show that with an increase of 100 units, the incidence of MACE increased by 19% [50], underscoring the crucial predictive role of lipid load in adverse prognosis.

2.3 Joint Recognition of Vulnerable Plaque by Multimodality Imaging Tools

In addition to the aforementioned research on single intracoronary imaging technology, the ATHEROREMO-IVUS study uses the combination of IVUS-NIRS to demonstrate that TCFA defined by IVUS is related to the incidence of long-term (more than six months) ACS events. The short-term prognosis of patients will be affected by both PB $\geq 70\%$ and TCFA [51]. The average follow-up results of 4.7 years show that MLA and TCFA (and PB $\geq 70\%$) can independently predict the adverse prognosis of patients [52]. The PROSPECT2 study also redefined vulnerable plaque by combining NIRS with IVUS. Based on the original definition, it added max LCBI4mm ≥ 324.7 as a new standard to describe vulnerable plaque, optimizing the patient risk classification [53]. The study also suggests that lesions with large plaque burden and high lipid load index are associated with future undesirable cardiovascular

events. It indicates that early interventional therapy for vulnerable plaques may further achieve better outcomes. By identifying vulnerable plaques and people with high-risk characteristics via intracoronary imaging technology, targeted treatment may be realized, such as shortening follow-up intervals and strengthening drug therapy. However, this superiority still needs to be confirmed by numerous large-scale trials in this field. Moreover, the combination of OCT and IVUS was also used to explore the pathological features of ACS patients [54,55]. The various effects of these vulnerable characteristic are listed in Table 1 (Ref. [51–55]) and Fig. 1, respectively.

2.4 Dynamic Evaluation of Plaque Changes with Intracoronary Imaging Tools

In predicting the prognosis of patients, it may not be possible to precisely reflect the progression of plaque with only single, one-time points, since the progression is a dynamic process. Measuring OCT at different time points can delineate the vascular condition at different time points. Researchers can use markers such as side branches, calcification, and stent edges to identify the exact sites through different time points to obtain the continuous changes of plaque. Therefore, some studies evaluate plaque response to drugs or plaque progression through more than one time OCT measurement [56,57]. For example, the HUYGENS study evaluates the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on plaque by observing the change in fibrous cap thickness [56].

Notably, although OCT can observe the microstructure in the lumen, it cannot calculate plaque depth and area well because of its limited penetration depth. Multiple IVUS measurements are also used clinically to observe plaque change [58]. Some experiments combined IVUS and OCT show that statins can lead to plaque morphological changes, namely, fibrous cap thickening, plaque volume increase [59] and a reduced prevalence of ruptured plaque [60]. The recently released result of the PACMAN AMI study comprehensively evaluated the entire plaque of acute myocardial infarction (AMI) patients by combining IVUS-NIRS and OCT [61]. It observed the continuous composition and morphological changes of plaque *in vivo* [61]. These experiment not only enhanced the credibility of the conclusions but also paved a new way for accurate evalu-




Fig. 1. Common characteristics of vulnerable plaques on intracoronary imaging images. (a) $MLA = 2.51 \text{ mm}^2$ and macrophages (blue triangle) under OCT. (b) Low backscattering (white triangle) indicating $PB > 70\%$ under IVUS. (c) A thin fibrous cap plaque delineating necrotic core with an overlying fibrous cap (red arrow) where the minimum thickness of the fibrous cap is less than $65 \mu\text{m}$ defined by OCT.

ation and individualized treatment of plaque by combining the advantages and overcoming the disadvantages of three imaging methods.

3. Application of Coronary Physiological Tools in ACS

The concept of pressure-derived FFR was first introduced by Pijls in 1995 [62], and has been used in PCI guidance of simple and complex multi-vessel diffuse lesions in clinical practice. FFR was calculated as the ratio of mean distal coronary artery pressure (Pd) to proximal coronary artery pressure (Pd/Pa) by injecting intracoronary adenosine under the condition of maximum myocardial filling. Increasing evidence shows the safety and effectiveness of FFR in guiding the treatment of non-culprit lesions [63–65]. Generally, $FFR > 0.8$ indicates FFR-negative lesion; $FFR < 0.75$ indicates positive; while $0.75 < FFR < 0.8$ is the gray area of measurement [3].

Using FFR to guide the treatment of ACS patients can carry out targeted operations on the lesion areas with blood flow restriction (including culprit lesion and non-culprit lesions). The DANAMI-3-PRIMULTI study, by comparing FFR-guided lesion revascularization and complete revascularization in STEMI patients separately, noted that there was no statistical difference in all-cause mortality and non-fatal revascularization event rates between the groups. However, the complete revascularization group had a lower recurrence and lower probability of revascularization (both urgent and non-urgent) within two years after operation [66]. Similar findings were obtained in several studies, confirming the importance of complete revascularization [67]. These trials also emphasize the importance of treating non-culprit lesions with blood flow restriction in ACS patients. Besides, the advantages of complete revascularization compared to revascularization for culprit lesions only are not only reflected in the reduced number of

subsequent revascularization lesions but also the compound outcome of long-term cardiovascular death or myocardial infarction [68].

Recently, FLAVOUR study [69] compared the interventional therapy of patients with moderate stenosis guided by FFR and IVUS. After 24 months of follow-up, FFR guidance was not inferior to IVUS guidance in combined major outcomes of death, myocardial infarction, or revascularization [69]. What's more, FFR-guided PCI and stent implantation strategies have also achieved better results in patients with ACS. A subgroup analysis of the FAME study confirms these findings through the secondary analysis of 325 NSTEMI and UA. The incidence of MACE after two years in PCI patients guided by FFR among these patients (5.1%) has no obvious difference compared with stable angina pectoris (SAP) (3.7%). In addition, FFR-guided procedures are less time-consuming than angiography, reducing patient exposure to contrast media and radiation [70]. The FUTURE study pointed out that FFR-guided PCI can reduce the proportion of lesions requiring revascularization without increasing the risk of ischemic cardiovascular events or death, thus reducing the economic burden of patients while reducing the risk of stent complications [71]. A prospective multicenter study on NSTEMI patients also pointed out that FFR-guided revascularization therapy has a higher proportion of conservative treatment without increasing the proportion of MACE, including cardiac death, hospitalization for myocardial infarction or heart failure [72]. Hospitalization time and economic burden are also reduced [73]. In addition, an experiment on 304,548 ACS patients to compare FFR-guided PCI with angiography-guided PCI showed that FFR-guided patients had less all-cause mortality and fewer complications such as bleeding and coronary dissection [74].

However, the routine use of FFR in ACS patients remains controversial [75]. Several studies note that FFR-guided revascularization did not show better results than the angiography-guided group [76]. Other studies also point out that compared with patients with SAP, ACS patients with delayed treatment of non-culprit lesions guided by FFR have a poorer prognosis and higher incidence of MACE [77,78]. The main reasons are as follows: (1) in the acute stage, the increase of adrenaline secretion may lead to excessive contraction of peripheral blood vessels and microcirculation. (2) The microvascular dysfunction caused by myocardial ischemia is not limited to the myocardium attached to the culprit artery, resulting in a false negative (FFR >0.8) [79,80]. Since measuring FFR in acute stage may underestimate the severity of ischemia, it is still necessary to surveil patients with negative FFR. (3) Some studies have shown that the FFR value of most non-culprit lesions is mainly concentrated in the “grey value” period of 0.75–0.80 [81,82]. As the treatment method cannot be determined by cutoff value alone, the accuracy of clinical diagnosis of FFR in ACS patients in the acute stage decreases accordingly. The physiological assessment of non-culprit lesions in acute stage by FFR will also underestimate the degree of stenosis to a certain extent, thus changing the treatment strategy. (4) FFR measurement during the initial operation may prolong the time of reperfusion, which may lead to higher risk, such as hemodynamic instability and arrhythmia [83]. Moreover, the FFR measurement may increase the possibility of complications of the operation [66]. Together, these data suggest that FFR-guided stenting does not show a consistent advantage on prognosis of ACS patients. The solution remains controversial and warrants more rigorous randomized controlled large-scale clinical trials for validation.

The clinical application of FFR is limited by its invasive and time-consuming nature. Among other limitations, some patients are intolerant of adenosine, and the results are easily affected by microcirculation conditions. As a result, new technologies such as transient waveform-free ratio (iFR), coronary angiography flow reserve fraction (CT-FFR), contrast agent-based FFR (QFR), OCT-based FFR (OFR) and IVUS-based FFR (UFR) are emerging as substitutes for FFR. Most of the new techniques have been proven to have good accuracy and reproducibility compared to FFR [84–90]. Among them, CT-FFR, though noninvasive and superior to CTA findings, is less accurate than FFR in the ACS population [90]. Interestingly, compared with FFR, iFR may even better reflect the actual state of epicardial blood flow in some cases, and the superiority of iFR has been confirmed in some literature [78]. Moreover, iFR does not require adenosine. Some studies demonstrate that the coronary physiological index, which is almost unaffected compared with FFR by microcirculation function, is obtained by measuring the pressure changes on both sides of the lesion during the wave-free period of diastole

[91]. However, it has also been suggested that in the acute phase, iFR may be subject to errors such as overestimation of the severity of non-culprit lesions due to increased resting coronary blood flow during ACS [91,92]. In the 2018 ESC/EACTS guidelines, FFR and iFR are both recommended for evaluating moderate stenotic lesions (Class IA), when evidence of ischemia is not available [3].

In addition to the hemodynamics of the epicardial vessels, microcirculatory resistance is also an important indicator of prognosis [93,94]. As mentioned previously, IMR is an invasive indicator of the minimum achievable myocardial microvascular resistance. Several studies have demonstrated that IMR values assessed at the time of primary PCI are strongly associated with microvascular obstruction (MVO) [95] and poor prognosis, mainly due to heart failure and malignant arrhythmias [93]. The OxAMI-PICSO study redistributed blood from distant non-ischemic myocardium to the ischemic zone by using pressure-controlled intermittent coronary sinus occlusion (PICSO) patients with IMR >40 prior to stent placement with periodic balloon inflation in the coronary sinus. The results showed the final infarct size is smaller in the intervention group, providing preliminary evidence of the feasibility of using intraoperative IMR guidance for adjuvant therapy in the STEMI population [96]. Remaining trials related to the use of IMR to guide treatment are ongoing, such as a large, randomized trial evaluating the feasibility of delayed stent placement in STEMI patients by exploring the use of IMR values (NCT03581513). Other ongoing research includes the exploration of potential drug treatment options (NCT02894138 and NCT03998319).

4. Optimization of Risk Stratification by Combining Multimodal Diagnostic Tools

The studies discussed above show that it is not sufficient to guide the revascularization of ACS patients only via intracoronary imaging or coronary physiological tools. Currently, a series of experiments combining plaque vulnerability characteristics and coronary physiology is being carried out to improve the prognostic risk classification of different patients. In the ABSORB study, researchers measured the intracoronary NIRS-IVUS imaging of three vessels in patients with myocardial infarction after PCI and implanted stents for vulnerable plaques IVUS-PB $\geq 65\%$ without blood flow restriction. Results showed that stent treatment for large lipid plaques is safe and effective, significantly increasing the MLA of vessel and long-term positive outcomes [97].

The COMBINE (OCT-FFR) study is a large-scale multicenter prospective, double-blind international study consisting of 547 patients also diagnosed with diabetes. In this trial, culprit plaque and plaques with severe visual estimated stenosis by angiography of ACS patients have been revascularized before. The results showed that although some non-culprit lesions (40%–80% obstruction

Table 2. The summary of studies for both coronary physiology and intracoronary imaging-guided PCI.

	People	Number	Technology	Follow up time	Result	Reference
PROSPECT ABSORB	ACS	182	FFR/iFR IVUS	25 months	PCI of angiographically mild lesions was safe and substantially enlarged the follow-up MLA.	[97]
COMBINE	Diabetic mellitus patients with SAP or ACS	547	OCT FFR	18 months	Patients with ≥ 1 FFR-negative lesions, TCFA-positive patients represented 25% of this population and were associated with a five-fold higher rate of MACE.	[98]
PECTUS-obs	STEMI and NSTEMI	439	OCT FFR	/	ongoing	[99]

ACS, Acute Coronary Syndrome; SAP, Stable Angina Pectoris; MLA, Minimum Lumen Area; MACE, Major Adverse Cardiovascular Events.

during angiography by visual examination) were FFR negative (FFR < 0.8), the incidence of target lesion-related MACE in TCFA patients after one year was higher than that in patients without TCFA. The researchers' conclusion did not change when analyzing ACS patients alone [98]. The results confirm that the combination of FFR and OCT can improve the accuracy of identifying vulnerable non-culprit lesions. However, the main population discussed in this study is the diabetic population. Whether their conclusion can be generalized to the general ACS population remains to be studied.

To further validate this idea, an ongoing prospective study (NCT03857971) used both FFR and OCT in 439 patients with ACS to identify the potential impact of preventive PCI in non-culprit lesions with vulnerable traits in the absence of flow restriction on patient prognosis and to prove the necessity of this treatment strategy [99]. As mentioned above, because of the time-consuming and financial burden of combining FFR measurement with other intracoronary imaging tools, using some emerging technologies (such as OFR and UFR) in combination with OCT and IVUS to guide PCI treatment may avoid the potential complexity associated with FFR operation while improving its accuracy. The representative studies are listed in Table 2 (Ref. [97–99]).

QFR, OFR, and UFR are coronary function indexes calculated based on angiography as well as OCT and IVUS images; they demonstrate accuracy and repeatability. Compared with FFR, these technology may also reduce the secondary guidewire's potential damage and additional costs. Currently, QFR has been widely accepted, and its safety and superiority have been confirmed [100]. The accuracy of QFR compared to FFR was also confirmed in the ACS population [87,88]. Studies have also confirmed the predictive role of QFR in the prognosis of ACS patients and recommended it as a new tool for risk stratification and therapeutic management [101,102]. OFR with OCT high-resolution images is better than QFR with traditional images, as it is less affected by the original scaffold [103]. When FFR ≤ 0.8 is used as the cutoff value to define blood flow restriction, the overall diagnostic accuracy of OFR is 90%, and the sensitivity and specificity are 87% and 92%,

respectively [104]. Since OCT is recommended for use in ACS patients to evaluate coronary lesions [3], OFR may more effectively evaluate non-culprit lesions and help realize the concept of complete physiological revascularization. The accuracy of UFR has recently been verified [86]. Good diagnostic accuracy and low observer variability may improve its effectiveness. One such study has already demonstrated that OFR combined with plaque features can help identify high-risk non-culprit lesions [105]. However, as OFR or UFR measurement in China has not been fully automated, its accuracy still needs to be confirmed in more extensive prospective studies. As yet, no clinical trials have applied these techniques to guide patient treatment in clinical settings. Future investigations and clinical applications of imaging-based coronary function indices still need to be explored.

5. Summary

In the past ten years, intracoronary imaging technology has guided and optimized the diagnosis and treatment of ACS patients. Concurrently, use of coronary physiological tools has enriched our perspective in evaluating coronary lesions, providing new insights into the pathogenesis of atherosclerosis and the pathophysiology of ACS. These tools have further improved treatment strategy and prognosis. Until now, coronary intervention technology has moved from the original 'one size fits all' modality to a new era of 'precise intervention'. The combination of the two technologies may improve the prognostic stratification of patients, while the generation of FFR substitutes (such as OFR and UFR) can avoid additional harm to patients due to the operation of FFR measurement. It is promising that the integrated assessment of both techniques will be clinically essential to improve the risk stratification of ACS patients and optimize the treatment process for PCI. Combining this substitute with intracoronary imaging may be a new strategy to guide ACS in the future.

Author Contributions

QS—manuscript conception, design and writing; ML—English editing and critical review of the manuscript; MZ—critical review of the manuscript; HJ—final approval of the manuscript.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest.

References

- [1] Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J, *et al.* Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. *American Heart Journal*. 2016; 175: 56–65.
- [2] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, *et al.* Fourth Universal Definition of Myocardial Infarction (2018). *Journal of the American College of Cardiology*. 2018; 72: 2231–2264.
- [3] Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, *et al.* 2018 ESC/EACTS Guidelines on myocardial revascularization. *European Heart Journal*. 2019; 40: 87–165.
- [4] Jia H, Dai J, He L, Xu Y, Shi Y, Zhao L, *et al.* EROSION III: A Multicenter RCT of OCT-Guided Reperfusion in STEMI With Early Infarct Artery Patency. *JACC: Cardiovascular Interventions*. 2022; 15: 846–856.
- [5] Park D, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, *et al.* Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. *The Journal of the American Medical Association*. 2014; 312: 2019–2027.
- [6] Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, *et al.* 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *European Heart Journal*. 2018; 39: 119–177.
- [7] Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, *et al.* A prospective natural-history study of coronary atherosclerosis. *The New England Journal of Medicine*. 2011; 364: 226–235.
- [8] Johnson TW, Räber L, di Mario C, Bourantas C, Jia H, Mat-tesini A, *et al.* Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *European Heart Journal*. 2019; 40: 2566–2584.
- [9] Montone RA, Niccoli G, Crea F, Jang I. Management of non-culprit coronary plaques in patients with acute coronary syndrome. *European Heart Journal*. 2020; 41: 3579–3586.
- [10] Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, *et al.* Optical coherence tomography. *Science*. 1991; 254: 1178–1181.
- [11] Yock PG, Linker DT, Angelsen BA. Two-dimensional intravascular ultrasound: technical development and initial clinical experience. *Journal of the American Society of Echocardiography*. 1989; 2: 296–304.
- [12] Park S, Kim Y, Park D, Lee S, Kim W, Suh J, *et al.* Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. *Circulation. Cardiovascular Interventions*. 2009; 2: 167–177.
- [13] Tan Q, Wang Q, Liu D, Zhang S, Zhang Y, Li Y. Intravascular ultrasound-guided unprotected left main coronary artery stenting in the elderly. *Saudi Medical Journal*. 2015; 36: 549–553.
- [14] Moreno PR, Lodder RA, Purushothaman KR, Charash WE, O'Connor WN, Muller JE. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. *Circulation*. 2002; 105: 923–927.
- [15] Araki M, Park S, Dauerman HL, Uemura S, Kim J, Di Mario C, *et al.* Optical coherence tomography in coronary atherosclerosis assessment and intervention. *Nature Reviews. Cardiology*. 2022; 19: 684–703.
- [16] Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, *et al.* Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. *Journal of the American College of Cardiology*. 2006; 48: 81–88.
- [17] Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, *et al.* Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. *Journal of the American College of Cardiology*. 2012; 59: 1058–1072.
- [18] Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlen-dorf KH, *et al.* Characterization of human atherosclerosis by optical coherence tomography. *Circulation*. 2002; 106: 1640–1645.
- [19] Hu S, Yonetsu T, Jia H, Karanasos A, Aguirre AD, Tian J, *et al.* Residual thrombus pattern in patients with ST-segment elevation myocardial infarction caused by plaque erosion versus plaque rupture after successful fibrinolysis: an optical coherence tomography study. *Journal of the American College of Cardiol-ogy*. 2014; 63: 1336–1338.
- [20] Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. *Circulation*. 1989; 79: 733–743.
- [21] Niccoli G, Montone RA, Di Vito L, Gramegna M, Refaat H, Scalone G, *et al.* Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. *European Heart Journal*. 2015; 36: 1377–1384.
- [22] Libby P, Pasterkamp G, Crea F, Jang I. Reassessing the Mechanisms of Acute Coronary Syndromes. *Circulation Research*. 2019; 124: 150–160.
- [23] Fahed AC, Jang I. Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions. *Nature Reviews Cardiology*. 2021; 18: 724–734.
- [24] Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, *et al.* In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. *Journal of the American College of Cardiol-ogy*. 2013; 62: 1748–1758.
- [25] Cao M, Zhao L, Ren X, Wu T, Yang G, Du Z, *et al.* Pancor-onary Plaque Characteristics in STEMI Caused by Culprit Plaque Erosion Versus Rupture: 3-Vessel OCT Study. *JACC: Cardio-vascular Imaging*. 2021; 14: 1235–1245.
- [26] Jia H, Dai J, Hou J, Xing L, Ma L, Liu H, *et al.* Effective anti-thrombotic therapy without stenting: intravascular optical coher-ence tomography-based management in plaque erosion (the EROSION study). *European Heart Journal*. 2017; 38: 792–800.
- [27] He L, Qin Y, Xu Y, Hu S, Wang Y, Zeng M, *et al.* Predictors

- of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study. *EuroIntervention*. 2021; 17: 497–505.
- [28] Jia H, Kubo T, Akasaka T, Yu B. Optical Coherence Tomography Guidance in Management of Acute Coronary Syndrome Caused by Plaque Erosion. *Circulation Journal*. 2018; 82: 302–308.
- [29] Sugiyama T, Yamamoto E, Fracassi F, Lee H, Yonetsu T, Kakuta T, *et al.* Calcified Plaques in Patients With Acute Coronary Syndromes. *JACC: Cardiovascular Interventions*. 2019; 12: 531–540.
- [30] Fujino A, Mintz GS, Matsumura M, Lee T, Kim S, Hoshino M, *et al.* A new optical coherence tomography-based calcium scoring system to predict stent underexpansion. *EuroIntervention*. 2018; 13: e2182–e2189.
- [31] Zhang M, Matsumura M, Usui E, Noguchi M, Fujimura T, Fall KN, *et al.* Intravascular Ultrasound-Derived Calcium Score to Predict Stent Expansion in Severely Calcified Lesions. *Circulation. Cardiovascular Interventions*. 2021; 14: e010296.
- [32] Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, *et al.* Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *European Heart Journal*. 2018; 39: 3281–3300.
- [33] Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. *Circulation*. 2015; 131: 861–870.
- [34] Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, *et al.* Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. *Circulation. Cardiovascular Interventions*. 2014; 7: 285–293.
- [35] Ong P, Athanasiadis A, Borgulya G, Voehringer M, Sechtem U. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. *Journal of the American College of Cardiology*. 2011; 57: 147–152.
- [36] Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Cammà G, *et al.* Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. *European Heart Journal*. 2018; 39: 91–98.
- [37] Sueda S, Oshita A, Izoë Y, Kohno H, Fukuda H, Ochi T, *et al.* A long-acting calcium antagonist over one year did not improve BMIPP myocardial scintigraphic imaging in patients with pure coronary spastic angina. *Annals of Nuclear Medicine*. 2007; 21: 85–92.
- [38] Seo SM, Kim PJ, Shin DI, Kim T, Kim CJ, Min J, *et al.* Persistent coronary artery spasm documented by follow-up coronary angiography in patients with symptomatic remission of variant angina. *Heart and Vessels*. 2013; 28: 301–307.
- [39] Montone RA, Niccoli G, Russo M, Giaccari M, Del Buono MG, Meucci MC, *et al.* Clinical, angiographic and echocardiographic correlates of epicardial and microvascular spasm in patients with myocardial ischaemia and non-obstructive coronary arteries. *Clinical Research in Cardiology*. 2020; 109: 435–443.
- [40] Pirozzolo G, Seitz A, Athanasiadis A, Bekerredjian R, Sechtem U, Ong P. Microvascular spasm in non-ST-segment elevation myocardial infarction without culprit lesion (MINOCA). *Clinical Research in Cardiology*. 2020; 109: 246–254.
- [41] Vancheri F, Longo G, Vancheri S, Henein M. Coronary Microvascular Dysfunction. *Journal of Clinical Medicine*. 2020; 9: 2880.
- [42] Häner JD, Duband B, Ueki Y, Otsuka T, Combaret N, Siontis GCM, *et al.* Impact of Intracoronary Optical Coherence Tomography in Routine Clinical Practice: A Contemporary Cohort Study. *Cardiovascular Revascularization Medicine*. 2022; 38: 96–103.
- [43] Campisi G, Giovannelli L, Calvino F, Matranga D, Colella G, Di Liberto C, *et al.* HPV infection in relation to OSCC histological grading and TNM stage. Evaluation by traditional statistics and fuzzy logic model. *Oral Oncology*. 2006; 42: 638–645.
- [44] Araki M, Soeda T, Kim HO, Thondapu V, Russo M, Kurihara O, *et al.* Spatial Distribution of Vulnerable Plaques: Comprehensive In Vivo Coronary Plaque Mapping. *JACC Cardiovascular Imaging*. 2020; 13: 1989–1999.
- [45] Kubo T, Ino Y, Mintz GS, Shiono Y, Shimamura K, Takahata M, *et al.* Optical coherence tomography detection of vulnerable plaques at high risk of developing acute coronary syndrome. *European Heart Journal - Cardiovascular Imaging*. 2021. (online ahead of print)
- [46] Pinilla-Echeverri N, Mehta SR, Wang J, Lavi S, Schampaert E, Cantor WJ, *et al.* Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudy. *Circulation: Cardiovascular Interventions*. 2020; 13: e008768.
- [47] Ohashi H, Ando H, Takashima H, Waseda K, Shimoda M, Fujimoto M, *et al.* Diagnostic Performance of High-Resolution Intravascular Ultrasound for the Detection of Plaque Rupture in Patients With Acute Coronary Syndrome. *Circulation Journal*. 2019; 83: 2505–2511.
- [48] Kataoka Y, Puri R, Andrews J, Honda S, Nishihira K, Asaumi Y, *et al.* In vivo visualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. *Expert Review of Cardiovascular Therapy*. 2017; 15: 775–785.
- [49] Waksman R, Di Mario C, Torguson R, Ali ZA, Singh V, Skinner WH, *et al.* Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. *Lancet*. 2019; 394: 1629–1637.
- [50] Schuurman A, Voegindewey M, Kardys I, Oemrawsingh RM, Cheng JM, de Boer S, *et al.* Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. *European Heart Journal*. 2018; 39: 295–302.
- [51] Cheng JM, Garcia-Garcia HM, de Boer SPM, Kardys I, Heo JH, Akkerhuis KM, *et al.* In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. *European Heart Journal*. 2014; 35: 639–647.
- [52] Schuurman A, Voegindewey MM, Kardys I, Oemrawsingh RM, Garcia-Garcia HM, van Geuns R, *et al.* Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology*. 2018; 72: 2003–2011.
- [53] Erlinge D, Maehara A, Ben-Yehuda O, Botker HE, Maeng M, Kjølner-Hansen L, *et al.* Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. *Lancet*. 2021; 397: 985–995.
- [54] Zhang W, Mintz GS, Cao Y, Matsumura M, Lee T, Hoshino M, *et al.* Clinical determinants of coronary artery disease burden and vulnerability using optical coherence tomography co-registered with intravascular ultrasound. *Coronary Artery Disease*. 2022; 33: 114–124.
- [55] Prati F, Gatto L, Romagnoli E, Limbruno U, Fineschi M, Marco V, *et al.* In vivo vulnerability grading system of plaques causing acute coronary syndromes: An intravascular imaging study.

- International Journal of Cardiology. 2018; 269: 350–355.
- [56] Nicholls SJ, Nissen SE, Prati F, Windecker S, Kataoka Y, Puri R, *et al.* Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. *Cardiovascular Diagnosis and Therapy*. 2021; 11: 120–129.
 - [57] Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, *et al.* Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. *JACC: Cardiovasc Imaging*. 2022; 15: 1308–1321.
 - [58] Endo H, Dohi T, Miyauchi K, Kuramitsu S, Kato Y, Okai I, *et al.* Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. *Journal of Cardiology*. 2019; 74: 102–108.
 - [59] Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, *et al.* Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. *JACC Cardiovascular Imaging*. 2012; 5: 169–177.
 - [60] Gili S, Iannaccone M, Colombo F, Montefusco A, Amabile N, Calcagno S, *et al.* Effects of statins on plaque rupture assessed by optical coherence tomography in patients presenting with acute coronary syndromes: insights from the optical coherence tomography (OCT)-FORMIDABLE registry. *European Heart Journal. Cardiovascular Imaging*. 2018; 19: 524–531.
 - [61] Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, *et al.* Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. *JAMA*. 2022; 327: 1771–1781.
 - [62] Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ, *et al.* Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *The New England Journal of Medicine*. 1996; 334: 1703–1708.
 - [63] Cho Y, Hwang J, Lee CH, Kim I, Park H, Yoon H, *et al.* Influence of Anatomical and Clinical Characteristics on Long-Term Prognosis of FFR-Guided Deferred Coronary Lesions. *JACC: Cardiovascular Interventions*. 2020; 13: 1907–1916.
 - [64] Smits PC, Abdel-Wahab M, Neumann F, Boxma-de Klerk BM, Lunde K, Schotborgh CE, *et al.* Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. *The New England Journal of Medicine*. 2017; 376: 1234–1244.
 - [65] Lee JM, Koo B, Shin E, Nam C, Doh J, Hwang D, *et al.* Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery disease. *European Heart Journal*. 2018; 39: 945–951.
 - [66] Engström T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, *et al.* Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet*. 2015; 386: 665–671.
 - [67] Elbadawi A, Dang AT, Hamed M, Eid M, Prakash Hiriyur Prakash M, Saleh M, *et al.* FFR- Versus Angiography-Guided Revascularization for Nonculprit Stenosis in STEMI and Multivessel Disease: A Network Meta-Analysis. *JACC. Cardiovascular Interventions*. 2022; 15: 656–666.
 - [68] Adams L. Acute coronary syndromes: Complete revascularization for STEMI. *Nature Reviews Cardiology*. 2017; 14: 254–255.
 - [69] Koo B, Hu X, Kang J, Zhang J, Jiang J, Hahn J, *et al.* Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. *The New England Journal of Medicine*. 2022; 387: 779–789.
 - [70] Sels JEM, Tonino PAL, Siebert U, Fearon WF, Van't Veer M, De Bruyne B, *et al.* Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. *JACC. Cardiovascular Interventions*. 2011; 4: 1183–1189.
 - [71] Rioufol G, Dérinay F, Roubille F, Perret T, Motreff P, Angoulvant D, *et al.* Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease. *Journal of the American College of Cardiology*. 2021; 78: 1875–1885.
 - [72] Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, *et al.* Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. *European Heart Journal*. 2015; 36: 100–111.
 - [73] Nam J, Briggs A, Layland J, Oldroyd KG, Curzen N, Sood A, *et al.* Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. *Cost Effectiveness and Resource Allocation*. 2015; 13: 19.
 - [74] Omran J, Enezate T, Abdullah O, Al-Dadah A, Walters D, Patel M, *et al.* Outcomes of fractional flow reserve-guided percutaneous coronary interventions in patients with acute coronary syndrome. *Catheterization and Cardiovascular Interventions*. 2020; 96: E149–E154.
 - [75] Göteborg M, Cook CM, Sen S, Nijjer S, Escaned J, Davies JE. The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. *Journal of the American College of Cardiology*. 2017; 70: 1379–1402.
 - [76] Puymirat E, Cayla G, Simon T, Steg P, Montalescot G, Durand-Zaleski I, *et al.* Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. *The New England Journal of Medicine*. 2021; 385: 297–308.
 - [77] Hakeem A, Edupuganti MM, Almomani A, Pothineni NV, Payne J, Abualsuod AM, *et al.* Long-Term Prognosis of Deferred Acute Coronary Syndrome Lesions Based on Nonischemic Fractional Flow Reserve. *Journal of the American College of Cardiology*. 2016; 68: 1181–1191.
 - [78] Escaned J, Ryan N, Mejía-Rentería H, Cook CM, Dehbi H, Alegria-Barrero E, *et al.* Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. *JACC: Cardiovascular Interventions*. 2018; 11: 1437–1449.
 - [79] Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. *The New England Journal of Medicine*. 1994; 331: 222–227.
 - [80] Niccoli G, Indolfi C, Davies JE. Evaluation of intermediate coronary stenoses in acute coronary syndromes using pressure guidewire. *Open Heart*. 2017; 4: e000431.
 - [81] Göteborg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, *et al.* Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. *The New England Journal of Medicine*. 2017; 376: 1813–1823.
 - [82] Petraco R, Escaned J, Sen S, Nijjer S, Asrress KN, Echavarría-Pinto M, *et al.* Classification performance of instantaneous wave-free ratio (iFR) and fractional flow reserve in a clinical population of intermediate coronary stenoses: results of the ADVISE registry. *EuroIntervention*. 2013; 9: 91–101.
 - [83] Hennigan B, Layland J, Fearon WF, Oldroyd KG. Fractional flow reserve and the index of microvascular resistance in patients with acute coronary syndromes. *EuroIntervention*. 2014; 10: T55–63.
 - [84] Jeremias A, Maehara A, Généreux P, Asrress KN, Berry C, De

- Bruyne B, *et al.* Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study. *Journal of the American College of Cardiology*. 2014; 63: 1253–1261.
- [85] Gutiérrez-Chico JL, Chen Y, Yu W, Ding D, Huang J, Huang P, *et al.* Diagnostic accuracy and reproducibility of optical flow ratio for functional evaluation of coronary stenosis in a prospective series. *Cardiology Journal*. 2020; 27: 350–361.
- [86] Yu W, Tanigaki T, Ding D, Wu P, Du H, Ling L, *et al.* Accuracy of Intravascular Ultrasound-Based Fractional Flow Reserve in Identifying Hemodynamic Significance of Coronary Stenosis. *Circulation: Cardiovascular Interventions*. 2021; 14: e009840.
- [87] Erbay A, Penzel L, Abdelwahed YS, Klotsche J, Schatz A, Steiner J, *et al.* Feasibility and diagnostic reliability of quantitative flow ratio in the assessment of non-culprit lesions in acute coronary syndrome. *The International Journal of Cardiovascular Imaging*. 2021; 37: 1815–1823.
- [88] Ullrich H, Olschewski M, Belhadj K, Münzel T, Gori T. Quantitative Flow Ratio or Angiography for the Assessment of Non-culprit Lesions in Acute Coronary Syndromes: Protocol of the Randomized Trial QUOMODO. *Frontiers in Cardiovascular Medicine*. 2022; 9: 815434.
- [89] Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, *et al.* Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC: Cardiovascular Interventions*. 2016; 9: 2024–2035.
- [90] Ahres A, Simon J, Jablonkai B, Nagybaczoni B, Baranyai T, Apor A, *et al.* Diagnostic Performance of On-Site Computed Tomography Derived Fractional Flow Reserve on Non-Culprit Coronary Lesions in Patients with Acute Coronary Syndrome. *Life*. 2022; 12: 1820.
- [91] van der Hoeven NW, Janssens GN, de Waard GA, Everaars H, Broyd CJ, Beijinink CWH, *et al.* Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction. *JAMA Cardiology*. 2019; 4: 736–744.
- [92] Thim T, Götzberg M, Fröbert O, Nijveldt R, van Royen N, Baptista SB, *et al.* Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in Patients With ST-Segment Elevation Myocardial Infarction. *JACC: Cardiovascular Interventions*. 2017; 10: 2528–2535.
- [93] Scarsini R, Shanmuganathan M, De Maria GL, Borlotti A, Kotronias RA, Burrage MK, *et al.* Coronary Microvascular Dysfunction Assessed by Pressure Wire and CMR After STEMI Predicts Long-Term Outcomes. *JACC Cardiovascular Imaging*. 2021; 14: 1948–1959.
- [94] Maznyczka AM, Oldroyd KG, McCartney P, McEntegart M, Berry C. The Potential Use of the Index of Microcirculatory Resistance to Guide Stratification of Patients for Adjunctive Therapy in Acute Myocardial Infarction. *JACC: Cardiovascular Interventions*. 2019; 12: 951–966.
- [95] De Maria GL, Alkhalil M, Wolfrum M, Fahrni G, Borlotti A, Gaughran L, *et al.* Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI. *JACC: Cardiovascular Imaging*. 2019; 12: 837–848.
- [96] De Maria GL, Alkhalil M, Borlotti A, Wolfrum M, Gaughran L, Dall'Armellina E, *et al.* Index of microcirculatory resistance-guided therapy with pressure-controlled intermittent coronary sinus occlusion improves coronary microvascular function and reduces infarct size in patients with ST-elevation myocardial infarction: the Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion study (OxAMI-PICSO study). *EuroIntervention*. 2018; 14: e352–e359.
- [97] Stone GW, Maehara A, Ali ZA, Held C, Matsumura M, Kjoller-Hansen L, *et al.* Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. *Journal of the American College of Cardiology*. 2020; 76: 2289–2301.
- [98] Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, IJsselmuiden AJJ, *et al.* Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. *European Heart Journal*. 2021; 42: 4671–4679.
- [99] Mol J, Belkacemi A, Volleberg RH, Meuwissen M, Protopopov AV, Laanmets P, *et al.* Identification of anatomic risk factors for acute coronary events by optical coherence tomography in patients with myocardial infarction and residual nonflow limiting lesions: rationale and design of the PECTUS-obs study. *BMJ Open*. 2021; 11: e048994.
- [100] Xu B, Tu S, Song L, Jin Z, Yu B, Fu G, *et al.* Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. *Lancet*. 2021; 398: 2149–2159.
- [101] Erbay A, Penzel L, Abdelwahed YS, Klotsche J, Heuberger A, Schatz A, *et al.* Prognostic Impact of Pancoronary Quantitative Flow Ratio Assessment in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. *Circulation: Cardiovascular Interventions*. 2021; 14: e010698.
- [102] Bär S, Kavaliauskaite R, Ueki Y, Otsuka T, Kelbæk H, Engström T, *et al.* Quantitative Flow Ratio to Predict Nontarget Vessel-Related Events at 5 Years in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Angiography-Guided Revascularization. *Journal of the American Heart Association*. 2021; 10: e019052.
- [103] Huang J, Emori H, Ding D, Kubo T, Yu W, Huang P, *et al.* Diagnostic performance of intracoronary optical coherence tomography-based versus angiography-based fractional flow reserve for the evaluation of coronary lesions. *EuroIntervention*. 2020; 16: 568–576.
- [104] Yu W, Huang J, Jia D, Chen S, Raffel OC, Ding D, *et al.* Diagnostic accuracy of intracoronary optical coherence tomography-derived fractional flow reserve for assessment of coronary stenosis severity. *EuroIntervention*. 2019; 15: 189–197.
- [105] Hong H, Jia H, Zeng M, Gutiérrez-Chico JL, Wang Y, Zeng X, *et al.* Risk Stratification in Acute Coronary Syndrome by Comprehensive Morphofunctional Assessment With Optical Coherence Tomography. *JACC: Asia*. 2022; 2: 460–472.